An Open-label, Single Sequence Crossover, Drug Interaction Study to Investigate the Effect of Linerixibat (GSK2330672) on Plasma Concentrations of Obeticholic Acid and Conjugates in Healthy Participants
Latest Information Update: 03 Jul 2023
At a glance
- Drugs Linerixibat (Primary) ; Obeticholic acid
- Indications Cholestasis; Primary biliary cirrhosis; Pruritus; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
Most Recent Events
- 09 Dec 2019 Status changed from active, no longer recruiting to completed.
- 20 Oct 2019 Status changed from recruiting to active, no longer recruiting.
- 10 Sep 2019 Status changed from not yet recruiting to recruiting.